about
A Possible Role of Anhedonia as Common Substrate for Depression and AnxietySex Differences in Kappa Opioid Receptor Function and Their Potential Impact on Addiction15 years of genetic approaches in vivo for addiction research: Opioid receptor and peptide gene knockout in mouse models of drug abuseDynorphin--still an extraordinarily potent opioid peptideRole of kappa-opioid receptors in stress and anxiety-related behavior.Drug withdrawal conceptualized as a stressor.The multiple facets of opioid receptor function: implications for addictionAsymmetry of the endogenous opioid system in the human anterior cingulate: a putative molecular basis for lateralization of emotions and pain.Neurobiology of aversive states.Kappa Opioids, Salvinorin A and Major Depressive DisorderMolecular mechanisms of synaptic remodeling in alcoholismA genetic polymorphism of the endogenous opioid dynorphin modulates monetary reward anticipation in the corticostriatal loopAnti-nociception mediated by a κ opioid receptor agonist is blocked by a δ receptor agonistOpiates Modulate Noxious Chemical Nociception through a Complex Monoaminergic/Peptidergic CascadeAblation of kappa-opioid receptors from brain dopamine neurons has anxiolytic-like effects and enhances cocaine-induced plasticityRecent progress in understanding the pathophysiology of post-traumatic stress disorder: implications for targeted pharmacological treatment.Affective cue-induced escalation of alcohol self-administration and increased 22-kHz ultrasonic vocalizations during alcohol withdrawal: role of kappa-opioid receptors.Corticotropin-releasing factor (CRF)-induced disruption of attention in rats is blocked by the κ-opioid receptor antagonist JDTic.Neuropharmacology of the naturally occurring kappa-opioid hallucinogen salvinorin AThe one-two punch of alcoholism: role of central amygdala dynorphins/kappa-opioid receptorsImpaired periamygdaloid-cortex prodynorphin is characteristic of opiate addiction and depression.Pain-related depression of the mesolimbic dopamine system in rats: expression, blockade by analgesics, and role of endogenous κ-opioids.Virus-mediated shRNA knockdown of prodynorphin in the rat nucleus accumbens attenuates depression-like behavior and cocaine locomotor sensitization.Searching for evidence of genetic mediation of opioid withdrawal by opioid receptor gene polymorphisms.Effects of kappa opioid receptors on conditioned place aversion and social interaction in males and femalesRole of the kappa-opioid receptor system in stress-induced reinstatement of nicotine seeking in rats.Role of kappa-opioid receptors in the effects of salvinorin A and ketamine on attention in ratsThe role of the dynorphin-kappa opioid system in the reinforcing effects of drugs of abuseDepressive-like effects of the kappa opioid receptor agonist salvinorin A are associated with decreased phasic dopamine release in the nucleus accumbensBehavioral stress may increase the rewarding valence of cocaine-associated cues through a dynorphin/kappa-opioid receptor-mediated mechanism without affecting associative learning or memory retrieval mechanismsThe role of kappa-opioid receptor activation in mediating antinociception and addiction.Sustained pain-related depression of behavior: effects of intraplantar formalin and complete freund's adjuvant on intracranial self-stimulation (ICSS) and endogenous kappa opioid biomarkers in rats.Long-acting κ opioid antagonists nor-BNI, GNTI and JDTic: pharmacokinetics in mice and lipophilicitySelective κ opioid antagonists nor-BNI, GNTI and JDTic have low affinities for non-opioid receptors and transporters.Identification of novel functionally selective κ-opioid receptor scaffolds.Distinct mu, delta, and kappa opioid receptor mechanisms underlie low sociability and depressive-like behaviors during heroin abstinence.Preliminary pharmacological evaluation of enantiomeric morphinans.Salvinorin A analogs and other κ-opioid receptor compounds as treatments for cocaine abuse.Safety, tolerability, and pharmacokinetic evaluation of single- and multiple-ascending doses of a novel kappa opioid receptor antagonist LY2456302 and drug interaction with ethanol in healthy subjects.Opioid hedonic hotspot in nucleus accumbens shell: mu, delta, and kappa maps for enhancement of sweetness "liking" and "wanting".
P2860
Q26752718-3B742F5A-C80D-40A2-A141-716F936FE620Q26770785-2EF67A10-30D8-4505-8A3B-7B620BDCF5A7Q26824667-1BC29538-F2F9-41A3-83B6-5F2809A24F90Q26860519-D1450532-ACC7-443A-A25C-1EB5AAF6DD60Q26991739-68E7283F-86FA-444E-B413-4145A89D6AD6Q26997989-B0228895-1C68-478F-B233-9DE9A0BF8C6DQ27005768-3CE93586-5928-433B-9439-CDF45E8EC91BQ27303172-F8AA6F0C-B07A-4169-9EB2-35942BC34E34Q27687846-797E2708-31F7-49B7-8518-9E80BF18EF03Q28075656-8A80FF51-37DB-494A-8598-E5284096E8E9Q28080843-69431FA1-A125-4C8A-A689-BF3204194F41Q28540133-8B663157-5FA1-43D6-B4D6-0BE605492CA9Q28652289-F031DB9E-0535-4BDE-9469-A2E90A880BAAQ28833838-DA1666CB-B38D-455F-9B4C-7EA82CF1146DQ30435816-3626173D-5C63-476F-9A50-F08B4893F12DQ30442231-7C7DFEF6-5313-49DA-B4F3-14C859EDC061Q30442446-ABCEC766-FEC3-403D-A2B9-7A4160CEDA77Q30446679-B9B533B2-E511-4708-BBD5-F350DE6EF3B0Q30467220-F1B36F64-39C3-43AB-9C46-4DA131EECB80Q30543310-42DEC59A-351D-46A9-96E5-239A18A56DFEQ30559281-2CF891E8-3226-4180-B746-B0B26136820FQ30565476-FD5BFF76-8910-4135-85D5-980D05BD80A0Q33591477-CA74C934-CB5D-44D8-BE77-56E34B015A7AQ33727027-E7446011-CF62-4A21-BF3F-D3005F19AE3FQ33814395-B73E2E42-4025-4DF7-80B0-A927B70DC65CQ33847097-883C8BA8-E2A3-407D-8B25-10179D80868BQ33848200-98CA4271-1AB7-4C22-B4DB-D498F17D0E99Q33890721-A6A7852C-E825-4E64-8AEF-C964DD51922DQ33951137-072C6B3B-5DA7-49E3-AC00-4F1CA71B0FF1Q33998470-2AA02AEA-5691-45CF-90BE-B576871F6260Q34132638-5ED3B63D-99EF-4785-834C-023B7B9C86BCQ34269299-DC72286E-2B3A-47A7-A9B9-BF0488E5B8F0Q34285100-7898D63F-9C82-467F-B29B-5EFACFAE1251Q34366661-DA445B28-E56E-4EB1-B15A-6ACFCA31BB0DQ34376764-DA076D87-FD0D-4E06-A7AD-DBE835D1381CQ34393118-077EE251-E1D2-4DDC-BDCC-A030D43DAB5FQ34395984-32D21640-890F-49F4-A5CC-90485BE2F889Q34401390-935AC7F5-9123-429C-8DBB-C28BECF5188EQ34409641-56A360AD-A4F1-4266-B375-49C9232A6D63Q34411031-AF4989A3-B3AC-485F-8ED0-C1CBFF73CB87
P2860
description
2010 nî lūn-bûn
@nan
2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Dynorphin, stress, and depression
@ast
Dynorphin, stress, and depression
@en
Dynorphin, stress, and depression
@nl
type
label
Dynorphin, stress, and depression
@ast
Dynorphin, stress, and depression
@en
Dynorphin, stress, and depression
@nl
prefLabel
Dynorphin, stress, and depression
@ast
Dynorphin, stress, and depression
@en
Dynorphin, stress, and depression
@nl
P2860
P3181
P1433
P1476
Dynorphin, stress, and depression
@en
P2093
Allison T Knoll
William A Carlezon
P2860
P3181
P356
10.1016/J.BRAINRES.2009.09.074
P407
P577
2010-02-16T00:00:00Z